Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Current therapy of myelodysplastic syndromes.

    ... therapeutic front, the approval of azacitidine , decitabine , and lenalidomide in the last decade was a major ...

    Research Article last updated 09/03/2013 - 12:03pm.

  2. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine.

    ... This retrospective analysis evaluated response to decitabine using updated IWG criteria in patients pooled from 2 decitabine trials. PATIENTS AND METHODS: Outcomes for patients with ...

    Research Article last updated 06/28/2013 - 1:20pm.

  3. Myelodysplastic syndromes: What do hospitalists need to know?

    ... therapy. The addition of azacitidine , decitabine , and lenalidomide to erythropoiesis-stimulating agents ...

    Research Article last updated 06/20/2013 - 10:59am.

  4. Prognostic role of immunohistochemical analysis of 5mc in Myelodysplastic Syndromes.

    ... effectiveness; the drugs azacitidine and decitabine have been approved for the treatment of MDS. METHOD: We ...

    Research Article last updated 06/20/2013 - 10:57am.

  5. Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine.

    ... AML and survival in 163 patients with MDS treated with decitabine 15 mg/m(2) over 3 hours every 8 hours for 3 days every 6 weeks ... should be considered for other interventions in addition to decitabine treatment. Bone ...

    Research Article last updated 01/02/2013 - 2:53pm.

  6. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

    ... hypomethylating agents (HMAs) azacitidine and decitabine have changed the treatment landscape of myelodysplastic ...

    Research Article last updated 01/03/2013 - 9:48am.

  7. Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis

    ... than that in the unmethylated group (p  =  0.094), decitabine treatment restored p73 expression and increased the level of ...

    Research Article last updated 11/05/2012 - 10:10am.

  8. Myelodysplastic syndromes: therapy and outlook

    ... such as lenalidomide , azacitidine , and decitabine are available for those who previously would have received ...

    Research Article last updated 07/31/2012 - 1:27pm.

  9. Combination strategies in myelodysplastic syndromes.

    ... lenalidomide , azacitidine , and decitabine are the only three FDA-approved drugs for MDS. Traditional ...

    Research Article last updated 04/24/2012 - 2:18pm.

  10. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

    ... for targeted therapies. Epigenetic therapy using decitabine , a DNA hypomethylating agent, is clinically effective for the ... at baseline did not correlate with clinical response to decitabine, we observed a significant correlation between reduced methylation ...

    Research Article last updated 10/11/2011 - 5:58pm.